-
Coding References
Learn
Solutions
- Subscription Options
CMS Granted J-Codes for Chiesi Products - 1/9/24
Effective January 1, 2024 EFFECTIVE JANUARY 1, 2024 xx NEW J-Code: J2508 xx Elfabrio is indicated for the treatment of adults with confirmed Fabry disease. Please see Important Safety Information below and Full Prescribing Information . xx New J-Code: J0127 x Lamzede is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. Please see Important Safety Information below and Full Prescribing Information . HCPCS Code Information Drug Elfabrio Lamzede J-Code J2508 J0217 Descriptor Injection, pegunigalsidase alfa-iwxj, 1 mg Injection, velmanase alfa-tycv, 1 mg HCPCS Code Dosage 1 MG 1 MG NDC Code Information Drug Elfabrio Lamzede Package Description One single-dose vial in a carton Five single-dose vials in a carton Ten single-dose vials in a carton One 10 mg single-dose vial in a carton NDC Code 10122-0160-02 10122-0160-05 10122-0160-10 10122-0180-02 WAC Per Package $4,135.11 $20,675.55 $41,351.10 $4,000.00 WAC Per…
Announcing a new Wholesale Acquisition Cost (WAC) for NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - 1/2/24
Announcing a new Wholesale Acquisition Cost (WAC) for NEXPLANON Effective January 2, 2024, the new WAC for NEXPLANON is $1,156.28 Please update your claims processing system and any applicable fee schedules for NEXPLANON as soon as possible. The price has been communicated to pricing services HCPCS Labeler 10 Digit NDC 11 Digit NDC Package Description WAC J7307 Organon 78206-145-01 xxxxxxxxxxxx 78206-0145-01 Single rod implant preloaded in disposable applicator $1,156.28 © 2023 Organon group of companies. All rights reserved. US-XPL-117012…
Sponsored Message: New FDA Approval in Locally Advanced/Metastatic Urothelial Cancer (mUC) - 1/3/24
Recent FDA Indication Approval in Locally Advanced/Metastatic Urothelial Cancer (mUC) Full Prescribing Information including BOXED WARNING NOW APPROVED! Now Approved in Combination With Pembrolizumab as a First-Line Treatment for Locally Advanced/ Metastatic Urothelial Cancer (mUC) Regardless of Cisplatin Eligibility Astellas Pharma Inc. and Seagen are pleased to announce the U.S. Food and Drug Administration (FDA) approval of PADCEV + pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) based on data from the EV-302 trial. This latest approval expands the indication of PADCEV + pembrolizumab and the patient population that may benefit from this treatment. Indication PADCEV ® , in combination with pembrolizumab, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC). PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who…
Permanent J-Code for BARHEMSYS® (amisulpride injection): Available January 1, 2024 - 12/20/2
Effective for claims on or after January 1, 2024: J0184 Injection, amisulpride, 1 mg HCPCS Code Information 1 : HCPCS Code J0184 HCPCS Code Descriptor Injection, amisulpride, 1 mg WAC per HCPCS Unit $9.00 NDC Information 2 : NDC Number Package Description WAC per Package 71390-0125-21 One single-dose vial containing 5 mg/2 mL of intravenous solution* $45.00 71390-0125-20 Bundle of 10 single-dose vials, each containing 5 mg/2 mL of intravenous solution $450.00 71390-0125-51 One single-dose vial containing 10 mg/4 mL of intravenous solution* $90.00 71390-0125-50 Bundle of 10 single-dose vials, each containing 10 mg/4 mL of intravenous solution $900.00 *Note: individual vial ordering is not available. For reimbursement questions, please contact: [email protected] . For additional information regarding Barhemsys, please contact your Key Account Manager or visit Barhemsys.com Indications Barhemsys is a selective dopamine-2 (D 2 ) and dopamine-3 (D 3 ) receptor antagonist…
No alerts match your filters.